| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
* Clinical Endocrinology Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health Bethesda, Maryland 20014
** Thyroid Unit, Department of Medicine, Peter Bent Brigham Hospital Boston, Massachusetts 02115
Serum thyroxine-binding globulin (TBG) was measured by radioimmunoassay. The human TBG used in this study was purified by affinity, anion-exchange, and gel filtration chromatography. The serum TBG concentration in 98 euthyroid normals was 1.48 ± 0.46 mg/lOO ml (mean ± SD), which is one-half that previously reported using a similar method. The level in females (1.66 ± 0.56) was significantly higher than that in males (1.37 ± 0.37). Comparison of the serum TBG level and the maximum binding capacity of serum TBG for thyroxine (T4) yielded a molar ratio of 1:1 for T4 and TBG. The mean serum TBG in 19 patients with hepatocellular carcinoma was 2.10 ± 1.29 mg/100 ml; however, only 2 of these patients had serum TBG levels outside the normal range.
Supported in part by NIH grant AM 18616 (PRL). PRL is an Investigator of the Howard Hughes Medical Institute.
Received August 11, 1975.
This article has been cited by other articles:
![]() |
R. B. Nelson Thyroxine-binding Globulin in Hepatoma Arch Intern Med, September 1, 1979; 139(9): 1063 - 1063. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |